Journal: Transplantation
Article Title: Longitudinal Pharmacokinetics of Everolimus when Combined with Low-level of Tacrolimus in Elderly Renal Transplant Recipients.
PMID/MRN: 27798513
Publication Date: 2016-Oct-28
Abstract:
Although the proportion of elderly patients among renal transplant recipients has increased, pharmacokinetic (PK) studies of immunosuppressants rarely include older patients.
We studied 12-hours everolimus (EVL) PK in 16 elderly renal transplant recipients (all caucasians; 10 males; mean age, 64±2 years, (61-71y), in 4 separate time-points (at 7, 30, 60 and 150 days) after EVL introduction, corresponding to a mean post renal-transplantation day: PK1 (43±4days), PK2 (65±7 days), PK3 (106±17 days) and PK4 (206±40 days). Patients received EVL (target trough level (Ctrough: 3-8 ng/mL), prednisone and tacrolimus (TCL) (target Ctrough: 2-5 ng/mL).
Mean TCL- Ctrough was 7.2±3.8, 4.9±2.2, 4.9±2.2, and 4.5±1.2 ng/mL at PK1, PK2, PK3 and PK4, respectively. There were no differences among time-points for mean EVL daily dose (data shown as PK3) (3.5±1.3 mg/day), Ctrough (4.7±2.5 ng/mL), AUC0-12h (106±51 ng*h/mL), Caverage (8.8±4.2 ng/mL), Cmax (19.2±9.7ng/mL), apparent Half-life (11.7±4.2 hours), estimated total body Clearance (0.39±0.27 L/hour), or Fluctuation (166±65%). Also, none of those PK parameters differed statistically when adjusted for body weight. EVL-Ctrough showed a very high correlation (r =0.849) with AUC0-12h.
Our data indicate that elderly renal transplant recipients starting EVL 1 month after transplantation along with a steady-state TCL level, present stable EVL-PK parameters without significant changes in dose or exposure during the first 6 months after renal transplantation.